ELEFANT

EARLY ELIMINATION OF FATTY ACIDS IN HYPERTRIGLYCERIDEMIA-INDUCED ACUTE PANCREATITIS (ELEFANT)

Acute pancreatitis (AP) is a common, life-threatening, high-mortality disease for which there is no specific drug therapy. In addition to treating AP, it may be advisable to eliminate and treat the triggering factor. Among the etiological factors, the third most common is hypertriglyceridemia, which causes AP with the most severe course and the highest mortality. Despite this, there are currently no available, uniformly applicable guidelines for the treatment of hypertriglyceridemia-induced (HTG)-AP.

ELEFANT is a randomized, controlled, multicenter, international trial, the purpose of which is to investigate the effectiveness of early triglyceride level reduction and to select the appropriate intervention method in patients with HTG-AP. Participants can be randomized into 3 groups: (1) those who undergo plasmapheresis and receive aggressive fluid resuscitation; (2) those who receive combined heparin and insulin therapy with aggressive fluid resuscitation; (3) and those who receive aggressive fluid resuscitation.

The ELEFANT study was presented during the following conferences:

28.11.2022: 11th CONFERENCE OF THE HUNGARIAN PANCREATIC STUDY GROUP (HPSG)

Dr. Péter J. Hegyi 

19/05/2023: Therapeutic apheresis course in memory of Prof. Dr. István Pénzes and Dr. Zoltán Vámos

Dr. Péter J. Hegyi 

07/03/2024: XXVII Transdanubian Diabetes Weekend

Dr. Péter J. Hegyi 

Principal Investigator: Prof. Dr. Péter Hegyi; email: hegyi2009@gmail.com
Leading coordinator: dr. Hegyi Péter J., email: drdunajskastreda@gmail.com
Additional centres may join the trial.
You may declare your intent to join this trial by filling in a Letter of Intent (to Join) and sending it to Péter Hegyi (hegyi2009@gmail.com).

Author Policy: Centers enrolling more than 20 patients in the study may have one author on the Authors List. The enrolment of every additional 20 patients provides the opportunity to name another author.
Approval ID: ETT TUKEB ad. 2460-4/2020/EÜIG.
Trial Registration Number: ISRCTN41530928